Literature DB >> 22187060

Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis.

Kamal Esalatmanesh1, Raika Jamali, Arsia Jamali, Bardia Jamali, Mohammadreza Nikbakht.   

Abstract

To define the relationship between serum anti-cyclic citrullinated peptide antibodies (anti-CCP) and disease activity, and to construct a new disease activity index by using anti-CCP in rheumatoid arthritis (RA). One hundred and five RA patients were included. Disease activity based on DAS28-ESR and serum anti-CCP was measured. There was correlation between serum anti-CCP and DAS28-ESR. (R (2) = 0.71, P value < 0.01). New disease activity index was developed by replacing anti-CCP with ESR in DAS28-ESR. There was correlation between new model and DAS28-ESR. (R (2) = 0.91, P value < 0.01) The new composite index best cut-off values corresponding to DAS28-ESR values of 2.6, 3.2, and 5.1 were 3.21, 3.38, and 4.74, respectively. There was agreement between new model and DAS28-ESR for determination of patients in different disease activity categories. (Kappa = 0.71, P value < 0.01). The new disease activity index that applies serum anti-CCP may predict disease activity in RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187060     DOI: 10.1007/s00296-011-2282-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis.

Authors:  Batool Zamani; Raika Jamali; Hassan Ehteram
Journal:  Rheumatol Int       Date:  2010-08-19       Impact factor: 2.631

2.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

3.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

Authors:  H A Chen; K C Lin; C H Chen; H T Liao; H P Wang; H N Chang; C Y Tsai; C T Chou
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

5.  Increased myeloperoxidase plasma levels in rheumatoid arthritis.

Authors:  Raissa Maria Sampaio Neves Fernandes; Neusa Pereira da Silva; Emília Inoue Sato
Journal:  Rheumatol Int       Date:  2011-02-18       Impact factor: 2.631

6.  Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population?

Authors:  Monchand Vanichapuntu; Puchaniyada Phuekfon; Parawee Suwannalai; Oravan Verasertniyom; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2009-07-12       Impact factor: 2.631

7.  Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity.

Authors:  Luis Rodríguez-Rodríguez; José Ramón Lamas; Jezabel Varadé; Pedro López-Romero; Pilar Tornero-Esteban; Lydia Abasolo; Emilio Gomez de la Concha; Juan Angel Jover; Elena Urcelay; Benjamín Fernández-Gutiérrez
Journal:  Rheumatol Int       Date:  2010-07-27       Impact factor: 2.631

8.  The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis.

Authors:  Hee Jung Ryu; Fujio Takeuchi; Shoji Kuwata; Yoon Jun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

9.  Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.

Authors:  Rim Sghiri; Elyes Bouagina; Hela Zaglaoui; Hajer Mestiri; Latifa Harzallah; Imed Harrabi; Mehdi Ghannouchi; Faycel Mokhtar; Ibtissem Ghedira
Journal:  Rheumatol Int       Date:  2007-04-20       Impact factor: 2.631

10.  Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.

Authors:  Bogdan Kolarz; Maria Majdan; Magdalena Dryglewska; Dorota Darmochwal-Kolarz
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

View more
  2 in total

Review 1.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

2.  Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis.

Authors:  Mehreen Inam Illahi; Sofia Amjad; Syed Mehfooz Alam; Syed Tousif Ahmed; Murk Fatima; Moazzam A Shahid
Journal:  Cureus       Date:  2021-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.